NFKB1 and Parkinson disease: In Parkinson's disease models, GSK3β activation has been shown to facilitate α‐synuclein aggregation and dopaminergic neuronal loss through mechanisms involving mitochondrial dysfunction, oxidative stress, and proinflammatory signaling pathways such as NF‐κB [32, 33, 34].